Resurrect Bio, a London, UK-based biotechnology company that supports the agriculture sector by equipping crops with genetic defenses against disease, has raised $8.1 million in the initial closing of its Series A funding round led by Corteva through its Corteva Catalyst platform.
The round also saw participation from Calculus Capital, Pymwymic, UKI2S, SynBioVen, and AgFunder.
Read More:LanzaJet Raises $47M in New Funding
The company plans to use the funds to accelerate its high-throughput trait discovery platform and move several disease-resistance products closer to commercial partnerships, delivering solutions to farmers much faster than traditional breeding methods.
Resurrect Bio is a biotechnology company working to strengthen crops with built-in genetic defenses against disease. Its proprietary platform combines FloraFold® AI computational biology with high-throughput plant screening to identify and restore disease-resistance genes weakened by pathogens. The process uses precise gene editing to make small changes to a plant’s existing genes helping the crop regain its natural ability to fight disease. This approach aims to give farmers a new way to protect yields from plant diseases that threaten global food security.
Dr. Cian Duggan, CEO of Resurrect Bio, said the company is pleased to receive investment from partners who share its goal of providing farmers with lasting disease resistance. With leadership from Corteva and support from Calculus Capital, Pymwymic, and existing investors, he said the company is ready to scale its platform and deliver multiple resistance traits to the seed industry.
Tom Greene, Senior Director at Corteva and Global Leader for Corteva Catalyst, said the partnership with Resurrect Bio marks another step toward developing new technologies that will give farmers more sustainable crop protection solutions. He added that Corteva is excited to collaborate on next-generation gene-editing tools to unlock greater potential from its leading germplasm.
Through its Corteva Catalyst platform, Corteva works with entrepreneurs and innovators to accelerate the development of early-stage, breakthrough technologies that help farmers produce more food and feed sustainably.
About Resurrect Bio
Resurrect Bio was founded in 2022 by Prof. Sophien Kamoun, Prof. Tolga Bozkurt, and Dr. Cian Duggan. Based in London and spun out of The Sainsbury Laboratory in Norwich, the company develops disease-resistant crops using its proprietary gene editing platform. By restoring natural resistance genes found in wild relatives and heritage varieties, Resurrect Bio offers the seed industry a sustainable alternative to chemical crop protection.
Read More:Axis Medical Receives Investment From Spur Ridge Capital
